Bristol Myers Squibb Shares Sold by Compagnie Lombard Odier

Institutional investor reduces stake in pharmaceutical company

Apr. 3, 2026 at 8:03am

Got story updates? Submit your updates here. ›

An extreme close-up of a series of gears, levers, and mechanical components in shades of steel grey, bronze, and black, conveying the intricate and powerful nature of financial institutions and the banking industry.The reduction in institutional ownership of Bristol Myers Squibb shares reflects the shifting tides of investor sentiment in the complex world of pharmaceutical finance.Princeton Today

Compagnie Lombard Odier SCmA, an institutional investor, reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 99.2% during the 4th quarter, according to the company's recent 13F filing with the Securities & Exchange Commission. The investor previously owned 2,000 shares of the biopharmaceutical company's stock, valued at $108,000 as of the last SEC filing.

Why it matters

This reduction in Bristol Myers Squibb's institutional ownership could signal a shift in investor sentiment towards the pharmaceutical company, though the reasons behind the sale are not entirely clear. Institutional investors like Compagnie Lombard Odier often play a significant role in shaping a stock's performance, so changes in their holdings are closely watched by the market.

The details

According to the 13F filing, Compagnie Lombard Odier SCmA sold 238,000 shares of Bristol Myers Squibb, leaving the investor with just 2,000 shares. The sale represents a 99.2% reduction in the investor's position in the company. Bristol Myers Squibb is a major biopharmaceutical company focused on developing and commercializing prescription drugs across various therapeutic areas, including oncology, immunology, and cardiovascular disease.

  • The share sale occurred during the 4th quarter of the reporting period.

The players

Compagnie Lombard Odier SCmA

An institutional investor that previously held a position in Bristol Myers Squibb Company.

Bristol Myers Squibb Company

A major biopharmaceutical company focused on developing and commercializing prescription drugs across various therapeutic areas.

Got photos? Submit your photos here. ›

The takeaway

The significant reduction in Compagnie Lombard Odier's stake in Bristol Myers Squibb could signal a shift in investor sentiment towards the pharmaceutical company, though the specific reasons behind the sale are not yet clear. Institutional investors like Compagnie Lombard Odier play an important role in shaping a stock's performance, so changes in their holdings are closely watched by the market.